Atara Biotherapeutics Stock Forecast
NASDAQ: ATRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ATRA analyst consensus
Consensus (3 analysts)
buy
Avg. price target
$13.67+44.20%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Atara Biotherapeutics (2026-10-09), 2 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $13.67, with a high estimate of $18.00 and a low estimate of $10.00. The average target implies upside of 44.2% from the current price of $9.48.
The spread between the highest and lowest targets is 80.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ATRA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 67% |
| Hold | 1 | 33% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $10.00 | +5.49% |
| Average target | $13.67 | +44.20% |
| High target | $18.00 | +89.87% |